Immunomic TherapeuticsImmunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax™ for use in the prevention and treatment of allergic diseases which resulted in over $315M in licensing revenue that year that established the Company as one of the leading entities in nucleic acid research. The company has focused on the application of its UNITE™ platform in oncology and most recently closed on a $61.3 financing led by HLB Co., LTD, a global pharmaceutical company focused on development novel cancer drugs.
